APLS (APLS)
Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Live quote temporarily unavailable — press releases and news are still shown below.
No company overview is available for APLS yet.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
Apellis Pharmaceuticals, Inc. — SC14D9C Filing
# 🧾 What This Document Is This is an **FAQ document** from Apellis Pharmaceuticals for its employees. It’s part of the official SEC filings related to the company's acquisition. Its purpose is to clearly explain the deal's details and directly answer the most pressing questions people inside the co
March 2026
Apellis Pharmaceuticals, Inc. — SC TO-C Filing
# 📄 What This Document Is This is the transcript of an investor conference call held on March 31, 2026. Biogen (BIIB) executives are explaining their proposed acquisition of Apellis Pharmaceuticals (APLS). Think of it as a live Q&A session where Biogen's leadership justifies the deal to Wall Stree
Apellis Pharmaceuticals, Inc. — 8-K Filing
# 🧾 What This Document Is This is an SEC **Form 8-K filing** that announces a major deal. It includes the full, legally binding **"Agreement and Plan of Merger"** between Apellis Pharmaceuticals (the target) and Biogen (the buyer). In simple terms, this document is the detailed rulebook for how Bio
Apellis Pharmaceuticals, Inc. — SC14D9C Filing
# 🧾 What This Document Is This is an SEC filing called a **Schedule 14D-9**. Think of it as a formal "Q&A and Announcement" document a company must file when someone is trying to buy it through a **tender offer**. It’s not the offer itself, but Apellis' official response and collection of related c
SEC filings
All filings →Insider trades
All insider trades →APLS has no reported insider trades in the last 90 days.